Retrospective Evaluation of Patients Diagnosed with Gestational Trophoblastic Disease in Our Clinic

InroductionGestational trophoblastic diseases (GTD) are a group of diseases that develop with abnormal proliferation of trophoblastic tissue, which originates from the placenta.Histologically, partial hydatiform mole (PHM), complete hydatiform mole (CHM) is classified as benign, while placental site trophoblastic tumor (PSTT), invasive mole and choriocarcinoma are classified as malignant.Today, GTD can be diagnosed at an early stage through ultrasonography (USG) and treated effectively (1,2).Vaginal bleeding is the main cause for hospital admission in patients diagnosed with CHM.BHCG values are higher than expected and the uterus may be large for gestational age (3).Patients with PHM, missed abortion or incomplete abortion findings may be observed.-hCG value may be detected lower than CHM.For this reason, PHM cannot be defined without histological examination(4).The incidence of hydatiform mole varies between 0.57 and 2 per 1000 pregnancies (5).We aimed to determine the clinical-pathological features by retrospectively evaluating the patients with benign GTD in our clinic. Materials and MethodsIn this study, 11,319 pregnant patients who were admitted to our hospital between 2015 and 2019 were evaluated, and the medical records and electronic files of those diagnosed with GTD were retrospectively reviewed.61 female patients over the age of 16 who had been diagnosed with benign GTD and were included in study.In addition to 3 patients diagnosed with Gestational trophoblastic Neoplasia (GTN), patients with missing medical and electronic records were excluded from the statistical analysis.Our study aimed to define the clinical-pathological features related to the clinical presentation and diagnosis of the disease by evaluating the patient's gravidity / parity / abortion numbers, B-HCG levels when the time Abstract Inroduction: In this study, we were aimed to determine the clinical-pathological features by retrospectively evaluating the patients diagnosed with benign Gestational Trophoblastic Disease (GTD) in our clinic. Materials and Methods:This study retrospectively analyzed 11,319 pregnant patients who were admitted to our hospital between 2015 and 2019.61 patients who were diagnosed with benign GTD, treated and followed up were included in the study.The patient's a ges, hospital admission complaints, ultrasound findings, serum B -HCG values, blood groups, gravidity, parity, number of miscarriages, histological GTD type and treatments were analyzed. Results:In GTD cases, 11.5% were aged below 21 years, while 23% were above 35 years.68.9% of the patients applied to our clinic with the complaint of vaginal bleeding, and 26% of the patient's received diagnosis during follow -up visits.The blood group distribution of GTD patients did not significantly differ from that of the general population, indicating that blood group A may not be an in dependent risk factor. Conclusion:Although there are many studies in the literature on the etiology and incidence of GTD, differences are observed in the data obtained since most of the studies are clinic-based.There is a need to increase community-based studies on this issue.Upon initial admission, 78.7% of patients were clinically suspected of having GTD.Thanks to advances in diagnostic methods, earlier diagn osis of the disease has become possible, contributing to a reduction in complications arising from the disease.Raising public awareness about the importance of earlier medical consultations during pregnancy or in cases of pregnancy suspicion is crucial.